The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...

The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...

Dietary strategies are commonly considered by people with IBD to manage symptoms and quality of life. This trial focuses on real-world adherence and patient-reported barriers to three popular diets (intermittent fasting,...

If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.

MR enterography is an important tool to measure transmural inflammation in ileal Crohn's disease, but many patients find the oral distension agents unpleasant. Demonstrating that non-distended MR enterography yields...

New analytical tools for longitudinal microbiome data can reveal time-varying microbial signatures tied to Crohn's disease and ulcerative colitis. Identifying such biomarkers may eventually inform diagnosis, monitoring,...

Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.

Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.

Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...

CDI is a common and important complication in people with IBD; which antibiotic is used can affect recurrence risk and subsequent need for surgery. This review pools available studies and suggests vancomycin may reduce...

HLH is a rare but serious complication in immunosuppressed IBD patients; visceral leishmaniasis can trigger HLH and may be overlooked outside endemic areas. Early bone marrow assessment can speed diagnosis and treatment.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Imaging. The original article is from Scandinavian Journal of Gastroenterology.

Hydrocortisone injection is an FDA‑labelled corticosteroid option for short‑term control of severe flares or life‑threatening situations when oral therapy isn't feasible; the label explicitly names regional enteritis...

The study identifies a compound (DDIE) that reduced cellular senescence and improved colitis in a mouse model by modulating AKT and GSK3B, suggesting a new avenue for drug development in ulcerative colitis focused on...

The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...

The study links paternal exposure to an emerging PFAS chemical (OBS) with epigenetic changes in sperm that may increase offspring susceptibility to colitis, highlighting a possible environmental pathway relevant to IBD...

Cure8 found this source from Nature genetics, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...

The study identifies a plant extract that reduced inflammation and oxidative stress and altered molecular pathways (Nrf2/Keap1, NF-κB) and lncRNA expression in a rat colitis model—potential leads for future IBD research...

The work suggests a microbe–metabolite–immune pathway (B. pseudolongum → taurine metabolites → M2 macrophages) that could point to future microbiome- or metabolite-targeted therapies for ulcerative colitis, which may be...

IBD may involve small-vessel changes beyond the gut. If reproducible, retinal microvascular alterations detectable by OCTA could offer a non-invasive window into systemic microvascular involvement in IBD.

People on biologic therapy who are not responding to standard doses may benefit from dose escalation — this study suggests escalation is common in routine care and linked with improved objective and patient‑reported...

Fatigue is a frequent, impactful symptom in IBD. Identifying that reduced physical fitness (rather than just lower day-to-day activity) is linked to fatigue points toward targeted fitness training as a potential way to...

The study maps cellular and molecular programs that drive transformation of fissures into fistulas in Crohn's disease, pointing to early remodeling processes and specific molecular pathways that could be targeted to...

The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.

The study suggests a herbal formula (H7F) may protect intestinal barrier function, modulate the gut microbiome, and suppress IL-17/NF-κB inflammation in a mouse colitis model—mechanisms relevant to IBD pathophysiology.

Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.

The review connects molecular cell-cycle changes to the progression from chronic IBD to colorectal cancer, pointing to pathways and cell-cycle regulators that could become prevention or treatment targets for...

Remote text monitoring is appealing as a low-cost way to support people with IBD on biologics, but this trial suggests it may not boost quality of life or adherence over 4 months when adherence is already high. Patients...

This study describes a new formulation of baicalein that improved drug solubility and oral absorption and showed benefit in a mouse model of ulcerative colitis—early-stage research that could inform future...

The findings suggest a processed herbal/tea preparation may alter gut metabolites and microbes to reduce colitis in mice, which could guide future dietary or translational research relevant to people with ulcerative...

Improved methods for profiling mucosa-associated microbiota from routine archival FFPE biopsies could expand research using stored pediatric gut samples, helping identify microbiome features linked to Crohn’s disease and...

This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.

Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...

This report links a rare kidney disease (FGN) with ulcerative colitis in a young adult and raises atypical familial Mediterranean fever as a possible underlying autoinflammatory cause; recognizing this could change...

This preclinical study reports that an extract of Anacyclus pyrethrum reduced colitis signs in a mouse DSS model and was linked to improved intestinal barrier markers, lower innate immune receptor expression, changes in...

People with IBD (including children) often have damaged gut barriers and altered microbiomes that can worsen inflammation and metabolic health. Dietary and nutritional approaches discussed here may help reduce...

GIB can present like Crohn's disease or appendicitis and lead to delayed diagnosis, repeated surgeries, and incorrect treatments. Recognizing this rare infection is important for people with unexplained,...

This study proposes a specific gene (PREX1) and related cytoskeletal pathways that may help explain epithelial brush-border and microvillus damage seen in IBD. Understanding these mechanisms could eventually inform new...

Vulvar Crohn’s is a rare, often treatment-refractory manifestation. Reports that ustekinumab and risankizumab helped patients may expand options for people with cutaneous Crohn’s disease, especially after anti–TNF...

Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.

Based on the title and source metadata, this appears to be a regulatory update related to Medications. The original article is from DailyMed.

Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...

Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...

Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...

A nationwide clinician survey identifies major variation in how acute severe ulcerative colitis is diagnosed, monitored, and when rescue therapy or surgery is used — differences that can affect patient outcomes and...

Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...

This survey shows IUS is increasingly recognized but underutilized in China due to limited training and varied perceptions across specialties; patients generally like IUS but many have safety concerns. Addressing...